Lurbinectedin in small cell lung cancer

Lurbinectedin in small cell lung cancer

Few treatment options are available for patients with small cell lung cancer (SCLC) in progression after a first-line therapy. A novel therapeutic approach is represented by lurbinectedin, a synthetic derivative of trabectedin that works by inhibiting oncogenic transcription and promoting apoptosis...

Full description

Bibliographic Details
Main Authors: Anna Manzo, Vincenzo Sforza, Guido Carillio, Giuliano Palumbo, Agnese Montanino, Claudia Sandomenico, Raffaele Costanzo, Giovanna Esposito, Francesca Laudato, Edoardo Mercadante, Carmine La Manna, Paolo Muto, Giuseppe Totaro, Rossella De Cecio, Carmine Picone, Maria Carmela Piccirillo, Giacomo Pascarella, Nicola Normanno, Alessandro Morabito
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
SCLC
lurbinectedin
topotecan
chemotherapy
second line
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.932105/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.932105/full

Similar Items